Background: To evaluate the efficacy of streptozocin and o,p'DDD (SO) in adrenocortical cancer (ACC) patients since other chemotherapeutic regimens have limited effects.
Introduction
Primary carcinoma involving adrenal cortex is very rare, comprising only two cases per million populations per year [1] . Treatment of advanced adrenocortical cancer (ACC) and the surgical treatment in earlier stages, with or without chemotherapy, are still controversial. The first-line treatment for ACC is surgical removal of all gross tumors. It can be curative in localized disease [2] [3] [4] . ACC recurs frequently and usually progresses rapidly. When complete resection is not possible, neartotal resection may still be helpful by reducing the amount of cortisol-secreting tissue [5, 6] . The use of cytotoxic agents alone or in combination such as cisplatin-containing chemotherapy did not prove to be effective [1, 7, 8] . o.p'DDD (1,1-dichloro-diphenyl-dichloroethanc, mitotane) was first introduced in 1960 [9] , and was the only drug associated with long-term remission, regression of metastases as well as increase of survival in ACC [10] [11] [12] [13] . The efficacy of o,p'DDD varied in different studies. Some experts did not recommend o.p'DDD due to its toxicity in dose ranges considered being therapeutic [14] [15] [16] . However, its adjuvant use has been suggested in several studies [10, [17] [18] [19] [20] . Streptozocin, an alkylating agent, employed in the treatment of gastrointestinal endocrine tumors, has been reported to concentrate in the mice adrenal cortex after intravenous injection [21] .
Streptozocin in combination with o,p'DDD has shown a beneficial effect in two out of three-advanced ACC in a previous study of our group [22] .
Over the past 20 years, we have evaluated and treated 40 patients with ACC. Three patients were described previously [22] . In this report, we evaluate our observations on 17 adjuvantly treated patients and compare them with a group of 11 non-treated cases following complete resection. The objective of the study was to evaluate the efficacy of the streptozocin and o,p'DDD (SO) combination chemotherapy on 40 ACC patients, conducted as a trial within the framework of the study group on Endocrine Abdominal Tumors of the Swedish Medical Research Council. Here, we also intended to identify the potential prognostic factors for ACC, emphasizing the clinical and hormonal characteristics of patients, as well as tumor stage.
Patients and methods

Patients
Forty patients with histologically verified ACC (26 women, 14 men), aged 20-69 years, were included in this study. Twenty-five patients had localized disease (stage I-II) and fifteen had metastases (stage 1II-IV) at the time of diagnosis. Six of them (stage I-II, n = 4 and stage III-IV, n = 2) were evaluated and treated according to our national protocol at other university hospitals (Stockholm and Lund). Twenty-two patients (stage I-II,n = 11 and stage III-IV, n = 11) were diagnosed at Uppsala and the remaining twelve patients (stage I-III) were referred to Uppsala from other local hospitals (with complete resection,« = 5 and with recurrence, n = 7).
Tumor classification and staging
Tumors were classified as functional (FT), when showing manifestations of excess steroid production, such as Cushing's syndrome, virilization or feminization; and non-functional (NF), when not associated with any clinical evidence of hormonal excess [23, 24] , The MacFarlane system modified by Sullivan was followed for staging of the tumors [25, 26] . Stage I-11 tumors are confined to the adrenal gland, stage III tumors have local invasion or positive lymph nodes and stage IV tumors are characterized by local invasion and lymph node or distant metastasis.
Methods
Clinical, radiological and biochemical evaluation of all the patients were done according to the standard procedures. Routine hematology, liver enzymes, serum creatinine, creatinine-clearance, urinary albumin were measured before the treatment was started as well as during treatment, at regular intervals, by collecting both peripheral blood and urinary samples.
The levels of serum cortisol, estradiol, testosterone, dehydroepiandrosterone sulfate (S-DHAS), 17-OH-progesterone, androstenedione were assessed to evaluate the therapeutic response or to detect recurrence. In addition to these, urinary cortisol, aldosterone, catecholamines were measured by radioimmunoassay. The urinary steroid profiles were monitored routinely as reported previously [22] .
Histopathologic examination of surgical specimens or biopsies included routine morphological study and the Grimelius silver nitrate staining.
CT scan and ultrasonography were done to assess the tumor shrinkage or progression. For further histopathological investigation, ultrasonically guided fine-needle biopsy was performed. To rule out bone metastases, a bone scan was performed. Chest X-ray was done every three months to exclude lung metastases.
Surgical treatment
Surgical removal of the tumor was attempted in 37 of the 40 patients. An apparently radical operation was performed in 28 patients (stage I-III). When complete resection could not be achieved, primary tumor was removed as much as possible, including resection of part of all organs involved and removal of involved lymph nodes. Complete resection could not be achieved in 6 patients with stage III-IV disease and 3 of 6 primarily inoperable cases were operated 5.5-18.5 months after pre-operative SO therapy. Sixteen of twenty-eight complete resection were done at different hospitals (at Lund, n -1, at Stockholm, n = 3 and at other sites, n -12). The operative reports of these patients were reviewed. Fifteen of the thirty-seven patients underwent a second operation for local recurrence or metastasis.
Medical treatment
This trial was carried out with the local ethical committees' approval. Informed consent was obtained from all patients. The SO was given to all patients either as adjuvant treatment following complete resection or in recurrent and or metastatic ACC (pre-and post-operatively) depending on their disease condition after referral. The chemotherapy was planned to be given until tumor recurrence or progression.
Streptozocin (Zanosar, from Pharmacia & Upjohn, Pea pack, New Jersey, USA) was given intravenously by a brief infusion with an induction course of 1 g/d (^0.5 g/m 2 ) for five days, thereafter 2 g
) every three weeks. The total number of courses varied in patients, ranging from 1-23 (median 7 courses). The median delivered dose of streptozocin was 17 g (range 5-49 g). Anti-emetic treatment, mainly serotonin-antagonists (5HT 3 -receptor blockers) have been used as pre-medication of streptozocin since 1988 with significant prevention of nausea and vomiting. o,p'DDD (Lysodren, from Bristol-Myers Syracuse, New York, USA) was administered orally at a relatively low dose of 1-4 g daily (median 3 g/d) in two to three divided doses according to the level of tolerance. Cortisone replacement (25-100 mg, hydrocortisone acetate) was given simultaneously with the o,p'DDD to avoid Addisonian crisis. The median duration of treatment was 5 months (range 1 week-20 months).
In our series of 28 radically operated ACC patients, 17 received SO as adjuvant therapy (at Uppsala) within 3 months of surgery with the exception of 2 cases. One patient, referred to our department four months after the removal of the primary tumor, received adjuvant treatment. In a 69-year-old woman with other associated diseases who was not physically fit for the time being, adjuvant therapy was started five months after radical operation. These 17 cases were compared with regard to disease-free interval (DFI) and survival with a group of 11 patients with no therapy following complete resection (at Lund, n = 1, at Stockholm, n = 3 and at other sites, n = 7). These later mentioned patients received the SO therapy only after relapse of the disease before or after second operation (at Lund, n -1, at Stockholm, n = 3 and at Uppsala, n = 7). Twelve ACC patients with metastases at diagnosis received the combination treatment either pre-or post-operatively or both with or without partial resection (at Stockholm, n = 2 and at Uppsala, n = 10).
Chemotherapeutic agents, such as OPEC (vincristin-cyclophosphamide-teniposide-cisplatin), CVB (cisplatin-vinblastin-bleomycin), CAP (cisplatin-adriamycin-cyclophosphamide), Taxol, cisplatin plus etoposide, or biological agents, such as interferon-alpha or suramin were tried after discontinuation of streptozocin when the disease progressed.
Definition of response
Clinical therapeutic response was determined according to WHO criteria; both as changes in the levels of the hormonal markers and tumor size measured radiologically [27] . It was classified as complete response (CR) when they had normal hormonal levels and no evidence of disease radiologically for at least four weeks; partial response (PR) when they had a more than 50% reduction of hormonal levels and/or tumor size for a minimum of four weeks. Stable disease (SD) was defined as a reduction of hormonal levels and/or tumor size by less than 50% and no appearance of new metastases for at least four weeks. Progressive disease (PD) was defined as an increase in hormonal levels/tumor mass more than 25%, or the appearance of new lesions.
Statistical analysis
The minimum number of radically operated ACC patients to be accrued in this study was 28 for comparison of DFI. Power of the test with regard to sample size was determined by using sampsi, Stata version 6.0. Statistical analyses of cumulative survival curves were plotted by the Kaplan-Meier method. Significance levels were calculated by log-rank (Mantel-Cox) test. The /'-value < 0.05 was considered significant. In addition to combination therapy, other prognostic factors such as sex and age of the patient, functional status and stage of tumor were also analyzed by using Cox proportional-hazards model. All values were expressed as median with range and/or mean with standard error of mean (mean ± SEM). 
Results
Patient characteristics and extent of disease
The median age at diagnosis was 44 years (range 20-69 years). It was similar with respect to sex (male: median 44 years, range 21-62 years, female: median 45 years, range 20-69 years) and functional status (FT: median 46 years, range 20-68 years; NF: median 43 years, range 26-69 years). The distribution according to sex and age of 40 patients showed a prevalence in females (female : male = 2:1) with a peak incidence at the sixth decade. Twenty-two patients (55%) had clinically FT; seventeen of them were women and five were men. Four (10%) of these patients had Cushing's syndrome, six (15%) had virilizing symptoms and twelve (30%) had both. Elevated serum steroids and pathological urinary steroid profiles confirmed hypersecretion of steroids in 20 cases. NF tumors were found in 18 (45%) cases (9 women, 9 men) and were diagnosed on the basis of non-specific symptoms, but 10 of them had positive biochemical evidence. Table 1 shows the functional status of all patients and measurements of steroids in serum, urine or both.
The main symptom at diagnosis in patients with NF tumors was abdominal pain (72%). Other presenting features, such as abdominal or other palpable mass (28%), fever (44%), fatigue (39%), sweating (11%), weight loss (50%) and hypertension (22%) were also observed. One NF case was incidentally found on renal sonography and another on urography, performed as screening for renal disease.
ACC coexisting with MEN-1 syndrome (multiple endocrine neoplasia, type-1) were detected in two cases (1 FT and 1 NF).
The mean time lapse from initial symptoms to diagnosis was 12 ± 2 months. The left adrenal gland was involved in 22 patients (55%) and the right adrenal in 16 (40%), while 2 patients (5%) had bilateral involvement. The median tumor size was 11 cm (range 5-25 cm). At diagnosis, 25 patients (62.5%) were found in stage I-II, remaining 15 (37.5%) in stage III-IV. Of our patients with stage I-II disease, 64% ultimately developed metastases in different organs. The major sites of tumor dissemination were liver (53%), para-aortal lymph nodes (33%), lungs (27%), bone (7%), adjacent kidney (7%) and inferior vena cava (7%) at diagnosis.
DFIand response
The efficacy of the SO was evaluated with regard to biochemical response, radiological change, DFI from operation to local recurrence or distant metastasis. Among the 28 patients (70%) who underwent curative intended surgery, the mean DFI was 49 ± 10 months (median 31 months, range 3-165 months). Seventeen (7 FT, 10 NF) of them who received the SO therapy as adjuvant had a significantly longer DFI than the remaining 11 patients (6 FT, 5 NF) who did not receive any therapy immediately after the operation (P = 0.02 and power, 66%). The mean DFI of adjuvantly-treated patients was 66 ± 14 months (median 49 months, range 4-165 months), 6 of them were free of disease at last follow-up (DFI: median 131 months, range 80-165 months) and 11 developed local recurrence or metastases (DFI: median 28 months, range 4-130 months). Two of these patients with recurrent ACC received the same combination therapy after a second operation and had a DFI of 36 and 50 months, respectively.
On the other hand, 11 radically operated patients who received this treatment only when local recurrences or metastases had developed, had a mean DFI of 22 ± 7 months (median 12 months, range 3-79 months). Among them, four had a second operation before the therapy was started. Only 1 of them was free of disease for 36 months after a second operation and underwent a third operation for recurrence, had a DFI of 8 years at last follow-up (patient no. 1 in Table 2 ). Therapeutic responses in the remaining 10 recurrent or metastatic ACC patients (Table 2) were; CR or PR (median 7 months, range 3-13.5 months) in 5 cases and SD in 3 cases, while the remaining 2 had PD.
Twelve patients were in an advanced stage in which surgery could not be curative. They received the combination therapy soon after diagnosis or after partial surgery (Table 3) . Three inoperable cases (25%) showed PR (median 9 months, range 5.5-18.5 months) following pre-operative treatment that allowed surgical resection of residual tumor. After surgery they received postoperative combination therapy. One of these patients was free of disease at last follow-up (DFI >18 years), one died due to breast cancer (DFI 10 years) and the third patient had SD at last follow-up (3 years after initial surgery). The remaining cases did not show any Table 2 . Therapeutic response of combination regimen ofo,p'DDD and streptozocin in recurrent or metastatic adrenocortical cancer (n = 11).
Patient no. (7) Radiological (months) PR (7) SD (2.5) PR (3) SD (3) PD PD CR (9) SD (16.5) SD (2.5) PR (7) Overall (months) PR (7) SD (2.5) PR (3) SD (3) PD PD CR (9) PR (13.5) SD (2.5) PR (7) response to the combination regimen except one whom had SD for three months. The combination therapy was changed to other chemotherapeutic agents in 21 of these 40 patients, when the disease progressed.
Survival
The mean survival of all patients was 64 ± 9 months (median 47 months, range 2-243 months). Out of 40 patients, 29 (72.5%) died because of complications of metastatic disease, while 11 (27.5%) were still alive with a mean survival of 138 ± 17 months (median 144 months, range 46-243 months) at last follow-up. Nine were free of disease, one had SD and one had a recurrence and was waiting for operation. Figure 1 shows the cumulative survival data for the 40 patients.
There was no influence of age, sex and functional status of the tumor on survival (P -0.38, 0.95 and 0.07, respectively), whereas tumor stage was found to have Time since diagnosis (months) Figure 2 . The effects of o.p'DDD and streptozocin on cumulative survival rales from the time of diagnosis in 28 radically operated cases (adjuvant n = 17 and non-adjuvant n = 11, P = 0.01 by log-rank test).
significant influence (P = 0.02). The estimated overall 2-year, 5-year as well as 10-year survival rates were 70%, 32.5% and 20%, respectively. The patients with complete resection (n -28; 25 in stage I-II, 3 in stage III) had a mean survival of 72 ± 10 months (median 53 months, range 16-219 months). Table 4 shows multivariate analysis of these 28 patients. Following complete resection, the patients who received adjuvant SO therapy, survived significantly longer than those who did not receive (P = 0.01, adjuvant vs. nonadjuvant) (Figure 2) . Eight of seventeen adjuvantly treated patients are still alive nine to fourteen years after diagnosis (median 11 years) and only one patient, who received the treatment on local recurrence, is alive with an exceptionally long survival of eighteen years.
The survival was shortest for the group receiving the therapy in initially advanced stage (mean 46 ± 21 months, median 16 months, and range 2-243 months). Two of three inoperable cases, who received therapy both pre-and post-operatively are still alive (4 and 20 years after diagnosis), while the third patient survived > 10 years and died due to breast cancer. Another three inoperable patients died within two to five months of diagnosis. The remaining patients (incompletely resected) had a shorter survival (mean 20 ± 8 months, median 16 months, and range 6-57 months).
Side effects
All patients were advised to take o,p'DDD continuously and increase their dose gradually to the highest tolerable level. However, sometimes, a reduction of dose or temporary withdrawal of the drug was required because of its adverse reactions. The major side effects observed, included gastrointestinal symptoms, such as nausea (n = 20) associated with anorexia (n -4) and vomiting (n = 4), as well as neurological disturbances, e.g., vertigo (n -7), lethargy (n -6), polyneuropathy (n = 2) and tiredness (n -12). Disturbances in liver enzymes were found in 25 patients (62.5%), that included increase in serum levels of alkaline phosphatase, aspartate aminotransferase (ASAT), alanine amino-transferase (ALAT) and lactate dehydrogenase (LD). However, autoimmune hepatitis (n = 3), gynecomastia (n -4), hemorrhagic cystitis (n = 1), microscopic hematuria (n = 2), skin rash (n = 2) and adrenolytic symptoms, i.e., Addisonism (n -4) were also recorded as adverse effects of o,p'DDD.
Streptozocin was given according to our schedule described before. In some patients, a reduction or, temporary withdrawal of the therapy was required. If the disease progressed, streptozocin was withdrawn permanently. The common side effects were gastrointestinal toxicity, such as nausea (n = 24) associated with vomiting (n -11) and diarrhea (« = 5), renal toxicity, including albuminuria (n -22), increased serum-creatinine level and reduced creatinine-clearance (n = 6).
Discussion
Due to the rarity of the diseases and absence of specific cancer-related early symptoms, 70% of the patients present with stage III or IV disease, which causes poor prognosis and short survival of the patients [1, 7, 15] . About 37.5% had metastases at the time of diagnosis in this study. Nowadays, it can be detected earlier and incidentally on abdominal computed tomography (CT) performed for other reasons [7, 25, 28] . In this study, two cases were found incidentally.
The mean time lapse from initial symptoms to diagnosis ranges from 6 to 14 months in previously published reports [10, 28, 29] and was 12 ± 2 months in the present study. Clinical characteristics of our patients with ACC support the previous reports. The tumor occurred more commonly in women with a peak incidence in the sixth decade of life, somewhat higher than has been described before. Women develop functional ACC:s more commonly than men [1, 7] , which is consistent with our series as 65% of women had FT. Cushing's syndrome associated with virilizing symptoms, was the clinical presentation in 54.5% of FT. NF malignant adrenal tumors are common in older patients in either sex [7] , and it is evident in our series. NF tumors were seen more often in patients above 40 years (67%) in both sexes, who mostly reported abdominal pain (72%). ACC commonly excrete excessive amounts of tetrahydro-11-deoxycortisol (THS), 3(3-hydroxy-5-ene-steroids or other steroid [22] , which was confirmed in 30 cases in this series.
The overall mean survival of treated patients reported by Wooten and King was 36 months [7] , and that of our patients is 64 months. The five-year survival rate in our series is 32.5%, indicating somewhat longer survival than that described in other studies (20%-30%) [10, 15, 24, 29] . This could be reflecting the use of the new combination therapy. Twenty-eight patients who underwent curative surgery, had a median DFI of 31 months which is 2.5 times longer than the median of 12 months observed in a previously published report [10] . We have found that to get the significance level of DFI at 0.05 and 90% power of the test, at least 20 patients are required in each group to perform a prospective adjuvant study. We also have found that the adjuvant combination therapy produced a mean survival of 84 ± 12 months. Schteingardt et al. [20] reported a mean survival of 74 ± 33 months with o,p'DDD alone as adjuvant; however, they included only 4 patients in their study.
In this present work, 36.4% of ACC patients with measurable disease (5 recurrent, 3 inoperable) showed CR/PR, while in another reported study [10] objective response was found in 22% of cases treated with o,p'DDD alone. Two of these inoperable cases were reported before [22] , one of them (FT) is still alive with the longest survival time of 20.3 years without showing any evidence of recurrence, while another (NF) survived for 10.5 years and died due to breast cancer.
The SO therapy at the dose we have used has fewer side effects than each of the drugs does at their previously recommended doses. It has been suggested that o,p'DDD should be given 5 g/d or more to achieve a significant therapeutic effect which very often produces intolerable side effects [7, 30] . We have used maximum 4 g/d of mitotane that had some side effects, however, most of the patients could tolerate it and the drug was withdrawn due to its adverse effects. The premedication, anti-emetic (serotonin-antagonist: 5HT 3 -receptor blocker) used for streptozocin since 1988 had positive effects on nausea and vomiting. Streptozocin was only withdrawn when the tumor progressed. Early diagnosis and adjuvant SO therapy following curative resection of the primary tumor, appears to have a significant effect on survival as well as on DFI in comparison to that observed in patients who did not have treatment. This combination regimen also appears to have a better effect than treatment with o,p'DDD alone or in combination with other forms of chemotherapy in recurrent or metastatic ACC: s. The relatively low dose of o.p'DDD used in the combination therapy is tolerable to the patients and 5HT 3 -receptor blocker as premedication helped the patients to overcome the adverse effects of streptozocin. This study indicates that our treatment regimen needs further evaluation with larger patient materials in randomized trials, where our results could be the basis for the evaluation of treatment responses.
